Dysesthesia enters the semaglutide label as a dose-related side effect

Semaglutide's prescribing information now names a side effect that most patients on standard doses have never heard of. With the approval of Wegovy HD 7.2 mg, an odd or altered skin sensation called dysesthesia appears on the label's list of most common adverse reactions, reported in 22% of patients taking the 7.2 mg dose compared with 6% at 2.4 mg and 0.3% on placebo ^[1].

The revised label, dated 03/2026, adds the 7.2 mg strength to the list of prefilled single-dose pens, which now deliver 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, or Wegovy HD 7.2 mg ^[1]. The "Recent Major Changes" box flags an update to Dosage and Administration in 03/2026 ^[1]. The usual recommended maintenance dose of Wegovy injection remains 2.4 mg once weekly, with doses for specific indications spelled out in the full prescribing information ^[1].

What dysesthesia means on the label

Dysesthesia refers to an abnormal or unpleasant skin sensation — tingling, burning, prickling or heightened sensitivity to touch. It now sits in the label's list of adverse reactions occurring in at least 5% of adults or pediatric patients aged 12 and older, alongside nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation (burping), hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and hair loss ^[1].

The pattern in the reported figures is dose-related: roughly a fourfold jump from the 2.4 mg maintenance dose to 7.2 mg, and a very low rate among people who received placebo ^[1]. That is why the finding surfaced only with the higher dose — at 2.4 mg and below, it had not been a prominent feature of the safety profile.

The sources provided do not describe how severe these sensations were, how long they lasted, whether they resolved with dose reduction or stopping the drug, how many patients left the trial because of them, or what might cause them. Those details are not yet known from the material available here.

The same label revision reflects other recent changes. A Warnings and Precautions section on suicidal behavior and ideation was removed in 01/2026 ^[1]. Warnings still in place include acute pancreatitis, acute gallbladder disease, hypoglycemia when combined with insulin or an insulin secretagogue, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions including anaphylaxis and angioedema, diabetic retinopathy complications in type 2 diabetes, heart rate increase, and pulmonary aspiration during general anesthesia or deep sedation ^[1]. The boxed warning about thyroid C-cell tumors in rodents remains, as does the contraindication for people with a personal or family history of medullary thyroid carcinoma or MEN 2 ^[1].

Why it matters for patients

Most people using Wegovy are on the 2.4 mg maintenance dose, where the reported dysesthesia rate was 6% versus 0.3% on placebo ^[1]. The 22% figure applies to the new higher-dose product ^[1]. Anyone considering a move to 7.2 mg now has a labeled number to weigh against the extra weight reduction the higher dose is meant to provide.

Practically, a labeled side effect also changes conversations. Skin tingling or burning has many possible causes, and having dysesthesia listed gives clinicians a documented reason to ask about it rather than treat it as unrelated. The label directs suspected adverse reactions to Novo Nordisk at 1-833-934-6891 or to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ^[1].

What happens next

The label carries a revision date of 03/2026 ^[1]. Separately, Wegovy's MASH indication for noncirrhotic disease with stage F2 to F3 fibrosis was granted under accelerated approval, and continued approval may depend on a confirmatory trial verifying clinical benefit ^[1]. No timeline for that trial's results appears in the available sources.